Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 9/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 15/20 | 0.58 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1668127 | 0.88 | PTGS1 (0.60) | PTGS1PTGS2MAPTPOLBCYP2C9 | |
| SCHEMBL2732241 | 0.84 | PTGS1 (0.56) | PTGS1PTGS2MAPTPOLBCYP2C9 | |
| SCHEMBL5212572 | 0.82 | PTGS1 (0.66) | PTGS1PTGS2MAPTPOLBCYP2C9 | |
| SCHEMBL7318838 | 0.81 | PTGS1 (0.64) | PTGS1PTGS2MAPTPOLB | |
| SCHEMBL14887386 | 0.81 | MAPT (0.67) | PTGS1PTGS2MAPTPOLBCYP2C9 | |
| SCHEMBL7319707 | 0.81 | PTGS1 (0.64) | PTGS1PTGS2MAPTPOLBCYP2C9 | |
| SCHEMBL7323516 | 0.81 | PTGS1 (0.64) | PTGS1PTGS2MAPTPOLBCYP2C9 | |
| SCHEMBL7242623 | 0.81 | PTGS1 (0.64) | PTGS1PTGS2MAPTPOLBCYP2C9 | |
| SCHEMBL1880301 | 0.79 | PTGS2 (0.51) | PTGS1PTGS2CRACR2ACYP2C9 | |
| SCHEMBL3278021 | 0.78 | PTGS1 (0.62) | PTGS1PTGS2MAPTPOLBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10668051-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2020-06-02 | — | — | US | disclosed |
| US-20190160046-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2019-05-30 | — | — | US | disclosed |
| US-10246450-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2019-04-02 | — | — | US | disclosed |
| US-20180222898-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2018-08-09 | — | — | US | disclosed |
| EP-2509955-B1 | PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS S A (CH) | 2018-04-25 | — | — | EP | disclosed |
| US-9944631-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-17 | — | — | US | disclosed |
| EP-3299361-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | Rhizen Pharmaceuticals S.A. (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-20170313690-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2017-11-02 | — | — | US | disclosed |
| US-9758514-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2017-09-12 | — | — | US | disclosed |
| US-20150166526-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| US-8921364-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20130310377-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | Rhizen Phamaceuticals SA (CH) | 2013-11-21 | — | — | US | disclosed |
| US-8377970-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-19 | — | — | US | disclosed |
| US-20110105447-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105447-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | PTGS1 1010/4885PTGS2 1000/4885CRACR2A 58/4885 |
| US-10668051-B2 | Modulators of calcium release-activated calcium channel | ORAI1, CACNB2, CACNB1 | PTGS1 917/4885PTGS2 830/4885CRACR2A 55/4885 |
| US-20170313690-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | PTGS1 1010/4885PTGS2 1000/4885CRACR2A 58/4885 |
| US-20190160046-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | PTGS1 1010/4885PTGS2 1000/4885CRACR2A 58/4885 |
| US-20130310377-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | PTGS1 1010/4885PTGS2 1000/4885CRACR2A 58/4885 |
| US-20150166526-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | PTGS1 1010/4885PTGS2 1000/4885CRACR2A 58/4885 |
| US-20180222898-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | PTGS1 1010/4885PTGS2 1000/4885CRACR2A 58/4885 |
| US-10246450-B2 | Modulators of calcium release-activated calcium channel | ORAI1, CACNB2, CACNB1 | PTGS1 917/4885PTGS2 830/4885CRACR2A 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.